Prurigo nodularis (PN) is a quintessential neurocutaneous condition characterized by neural sensitization and intractable itch leading to intense scratching. This causes the formation of nodules with epidermal thickening and further release of pro-inflammatory mediators that recruit immune cells and increase dermal nerve proliferation and hypertrophy perpetuating the itch-scratch cycle. Those with PN have a significant quality-of-life (QoL) burden due to itch, anxiety, and sleep disturbance. In addition, PN exhibits psychiatric comorbidities that affect mental wellbeing such as depression, mood disorders, and substance abuse. This paper serves as an overview of the clinicopathologic aspects of PN, the burden of PN on QoL, and the psychodermatological aspects of the disease state. J Drugs Dermatol. 2023;22:12(Suppl 2):s6-11.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.36849/JDD.SF365502 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of Metabolic Diseases in Patients With Prurigo Nodularis: A Systematic Review and Meta-Analysis.
Int J Dermatol
January 2025
Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA.
Editor's Highlights-February 2025.
Int J Dermatol
January 2025
Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
Understanding the pathophysiology of inflammatory skin diseases, including psoriasis, atopic dermatitis (AD), and prurigo nodularis (PN), has led to the development of innovative treatments. In the February issue of the Journal, we provide insight into the global epidemiology and psychosocial impact of psoriasis. We also discuss the role of tissue-resident memory T cells in disease recurrence and evaluate the effectiveness of tildrakizumab in treating difficult areas in psoriasis.
View Article and Find Full Text PDFC4d immunostaining facilitates differentiation of pemphigoid nodularis from prurigo nodularis.
Pathol Res Pract
December 2024
Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. Electronic address:
Pemphigoid nodularis and prurigo nodularis have similar clinicopathological features and are difficult to distinguish. Enzyme-linked immunosorbent assays (ELISA) and direct/indirect immunofluorescence can support the diagnosis of pemphigoid nodularis, but sometimes show contradictory results or are unavailable. We aimed to develop a practical method for differentiating between pemphigoid nodularis and prurigo nodularis.
View Article and Find Full Text PDFThe impact of dupilumab on sleep disruptions in patients with prurigo nodularis: A systematic review and meta analysis.
J Eur Acad Dermatol Venereol
December 2024
Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada.
IL-27 as a novel biomarker for pruritus in nodular prurigo and bullous pemphigoid.
Front Immunol
December 2024
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Introduction: Bullous pemphigoid (BP) and prurigo nodularis (PN) are chronic pruritic skin diseases that severely impact patients' quality of life. Despite the widespread attention these two diseases have garnered within the dermatological field, the specific pathogenesis, particularly the molecular mechanisms underlying the pruritus, remains largely unclear. Limited clinical sequencing studies focusing on BP and PN have hindered the identification of pathological mechanisms and the exploration of effective treatment strategies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!